In Japanese participants with type 2 diabetes, liraglutide and dulaglutide did not differ in incident-retinopathy risk (HR 0.98, 0.60-1.60; reference orientation not specified).
In plain wordsIn Japanese patients with T2D, liraglutide and dulaglutide showed no significant new retinopathy-risk difference.
- Peptide
- Liraglutide
- Outcome
- No significant changeDiabetic retinopathy incidence risk
- Study
n: not reported in source
- Comparator
- Dulaglutide
- Analysis
- Primary
- Outcome group
- Vision and retina · Eye
- Studied dose
- 0.9 mg once dailyAs given in this study (human).
Measurements
- Hazard ratio
- 0.98
- incident retinopathy; reported interval 0.60-1.60; reference orientation not specified
Source sentences
Over a mean follow-up of 4.4 and 3.6 years in the liraglutide and dulaglutide groups, respectively, there were no differences between the two groups in terms of the risk of incidence of retinopathy and reduced GFR (hazard ratio (HR): 0.98 [0.60-1.60] and 0.82 [0.36-1.84]).
6 context sentences(design, population, supporting numbers)
To evaluate and compare the risk of diabetic retinopathy and kidney disease between once-daily liraglutide and once-weekly dulaglutide in Japanese participants with type 2 diabetes (T2D).
A total of 341 participants newly initiated on once-daily liraglutide 0.9 mg or once-weekly dulaglutide 0.75 mg between 2015 and 2020 were included in this study.
We used propensity score-based inverse probability of treatment weighting to adjust for baseline characteristics between the two groups.
The participants were divided into three cohorts according to retinopathy, albuminuria, and glomerular filtration rate (GFR).
The primary outcomes were the incidence or progression of diabetic retinopathy or kidney disease (albuminuria or reduced estimated GFR (eGFR) 2).
The incidence rate and risk of outcomes were compared between the two groups using Poisson regression and Cox proportional hazard models.